Mr. Booma joined Anokion in 2022 as Chief Strategy Officer. He has deep experience leading product planning and portfolio strategy across a range of platforms and clinical indications. He has played a key role in the advancement of 15 programs into the clinic and approval/marketing of 6 products. Prior to Anokion, Glenn spent nearly a decade providing consulting to life sciences companies and investors, focused on portfolio strategy, new product commercialization and business development. Prior to this, Mr. Booma served as Senior Director, Strategic Market Development at Springleaf Therapeutics where he led the company’s portfolio strategy and commercial insights functions supporting financings, IND filing, and a successful first-in-human clinical program. Previously, he served in portfolio strategy and marketing roles at Cyberkinetics Neurotechnology Systems, Transform Pharmaceuticals (acquired by Johnson & Johnson), Control Delivery Systems (acquired by Psivida/EyePoint Pharmaceuticals), and Genzyme. Earlier, he was a business strategy consultant focused on the pharmaceutical and medical device industries at Charles River Associates and was a medical service representative at Pfizer. Mr. Booma holds a B.A. in biology from the University of Vermont and an M.S. in evaluative clinical sciences from Dartmouth College.